Electronic Cigarette Use
Conditions
Brief summary
The purpose of this research study is to determine if ethanol-containing e-cigarettes impact ethanol breath, blood or oral fluid tests, field sobriety tests, or other tests of sobriety. Ethanol is a common part of e-cigarette liquids.
Interventions
OTHERBeverage with ethanol and E-cigarette liquid with ethanol
Beverage with ethanol and E-cigarette liquid with ethanol
OTHERBeverage with ethanol and E-cigarette liquid without ethanol
Beverage with ethanol and E-cigarette liquid without ethanol
OTHERBeverage without ethanol and E-cigarette liquid with ethanol
Beverage without ethanol and E-cigarette liquid with ethanol
OTHERBeverage without ethanol and E-cigarette liquid without ethanol
Beverage without ethanol and E-cigarette liquid without ethanol
Sponsors
U.S. Department of Justice
Virginia Commonwealth University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
Single group assignment
Eligibility
Sex/Gender
ALL
Age
21 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* e-cigarette users * alcohol consumers * willing to provide informed consent * able to attend the lab sessions as needed * agree to use designated products according to study protocol.
Exclusion criteria
\- Women who are breast-feeding or test positive for pregnancy (by urinalysis) at screening.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | Oral fluid was collected before (baseline) and after (0, 5, 20, 40, 55, 200, 215, 240 min) drinking. The e-cigarette was used by the participant at 50 and 210 minutes post-drinking | Ethyl glucuronide was analyzed in oral fluid 9 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. |
| Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | Blood collected before (baseline) and after (0, 40, 55, 200, 215 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking. | 5-Hydroxytryptophol glucuronide was analyzed in blood 6 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. |
| Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | Blood collected before (baseline) and after (0, 40, 55, 200, 215 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking | Ethyl glucuronide was analyzed in blood 6 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. |
| Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | Oral fluid was collected before (baseline) and after (0, 5, 20, 40, 55, 200, 215, 240 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking | 5-Hydroxyindoleacetic acid was analyzed in oral fluid 9 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. |
| Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | Oral fluid was collected before (baseline) and after (0, 5, 20, 40, 55, 200, 215, 240 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking. | 5-Hydroxyindoleacetic acid was analyzed in oral fluid 9 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. |
| Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | Oral fluid was collected before (baseline) and after (0, 5, 20, 40, 55, 200, 215, 240 min) drinking. The e-cigarette was used by the participant at 50 and 210 minutes post-drinking | Ethyl sulfate was analyzed in oral fluid 9 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. |
| Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | Oral fluid was collected before (baseline) and after (0, 5, 20, 40, 55, 200, 215, 240 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking. | Phosphatidylethanol 16:0-18:1 was analyzed in oral fluid 9 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. |
| Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | Oral fluid was collected before (baseline) and after (0, 5, 20, 40, 55, 200, 215, 240 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking. | Phosphatidylethanol 16:0-18:2 was analyzed in oral fluid 9 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. |
| Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | Blood collected before (baseline) and after (0, 40, 55, 200, 215 min) drinking. The e-cigarette was used by the participant at 50 and 210 minutes post-drinking. | Ethyl glucuronide was analyzed in blood 6 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. |
| Blood Alcohol Concentration | Blood collected before (baseline) and after (0, 40, 55, 200, 215) drinking. The e-cigarette was used at 50 and 210 minutes post-drinking. | Blood alcohol concentration (BAC) level was determined 6 times over 6 hours to assess for changes in BAC from use of an e-cigarette containing ethanol compared to the use of an e-cigarette without ethanol. |
| Breath Alcohol Concentration | Breath was analyzed before (baseline) and after (10, 20, 40, 55, 90, 120, 165, 200, 215, 240, 270 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking. | Breath Alcohol Concentration (BrAC) was assessed 12 times over 6 hours to determine changes in BrAC from the use of an e-cigarette containing ethanol compared to the use of an e-cigarette without ethanol. |
| Oral Fluid Alcohol Concentration (OFAC) | Oral fluid was collected before (baseline) and after (0, 5, 20, 40, 55, 200, 215, 240 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking. | Oral fluid alcohol concentration (OFAC) was assessed 9 times over 6 hours to determine changes in OFAC from the use of an e-cigarette containing ethanol compared to use of an e-cigarette without ethanol. |
| Ethanol Biomarker (5-Hydroxytryptophol) in Blood | Blood was collected before (baseline) and after (0, 40, 55, 200, 215 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking. | 5-Hydroxytryptophol was analyzed in blood 6 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. |
| Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | Blood was collected before (baseline) and after (0, 40, 55, 200, 215 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking. | 5-Hydroxyindoleacetic acid was analyzed in blood 6 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. |
| Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | Blood was collected before (baseline) and after (0, 40, 55, 200, 215 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking. | Ethyl sulfate was analyzed in blood 6 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. |
| Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | Blood was collected before (baseline) and after (0, 40, 55, 200, 215 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking. | Phosphatidylethanol 16:0-18:1 was analyzed in blood 6 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. |
| Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | Blood was collected before (baseline) and after (0, 40, 55, 200, 215 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking. | Phosphatidylethanol 16:0-18:2 was analyzed in blood 6 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Walk and Turn Test | Conducted before drinking (baseline), at 20 minutes post-drinking (before first vaping bout), at 55 minutes post-drinking (after the first vaping), and at 215 minutes post-drinking (after second vaping bout). | Standard Field Sobriety Tests (SFSTs) were administered 4 times over a course of 6 hours to assess changes in objective impairment. The SFST includes the walk and turn test (suspect to perform a physical task while simultaneously following instructions and maintaining balance; involves walking a straight line heel-to-toe, turning, and walking back, with officers looking for specific indicators of impairment). For each test, a law enforcement officer records the number of clues observed. WAT has a maximum of 8 clues: 1. inability to balance during the instruction phase 2. starting before the officer has finished the instructions 3. Stopping while walking to regain balance 4. Not touching heel-to-toe 5. Stepping off the line 6. Using arms to balance 7. Losing balance on the turn or turning incorrectly 8. Taking the wrong number of steps |
| One Leg Stand Test | Conducted before drinking (baseline), at 20 minutes post-drinking (before first vaping bout), at 55 minutes post-drinking (after the first vaping), and at 215 minutes post-drinking (after second vaping bout). | Standard Field Sobriety Tests (SFSTs) were administered 4 times over a course of 6 hours to assess changes in objective impairment. The SFST includes the one-leg stand test (assess balance and coordination, potentially indicating impairment due to alcohol or drugs). For each test, a law enforcement officer records the number of clues observed. OLS has a maximum of 4 clues: Swaying while balancing, Using arms for balance, Hopping 4. Putting the raised foot down |
| Horizontal Gaze Nystagmus | Conducted before drinking (baseline), at 20 minutes post-drinking (before first vaping bout), at 55 minutes post-drinking (after the first vaping), and at 215 minutes post-drinking (after second vaping bout). | Standard Field Sobriety Tests (SFSTs) were administered 4 times over a course of 6 hours to assess changes in objective impairment. The SFST includes the Horizontal Gaze Nystagmus (a jerking or stuttering type of movement observed in a person's eyes that occurs as a result of consuming alcohol or other nervous system depressants) test. For each test, a law enforcement officer records the number of clues observed. HGN has a maximum of 6 clues, 3 per eye: 1. lack of smooth pursuit 2. distinct and sustained nystagmus at maximum deviation 3. onset of nystagmus prior to 45 degrees. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Direct Effects of Vaping Questionnaire (DEPVQ) | Administered at baseline, 55 minutes post-drinking (after first vape bout), and 215 minutes post-drinking (after second vape bout). | Direct Effects of Vaping Questionnaire (DEVQ) is a 10-item Questionnaire that asks participants about their vaping experience (10 questions, each scored from 0 - 100). While subscale scores are often the primary focus, an overall score may be calculated by summing all item scores or averaging them. The score for each of the questions was summed. A higher score indicates the e-cigarette evoked greater subjective effects or feelings. |
| Biphasic Alcohol Effects Scale Questionnaire (BAES) | Administered at baseline, 55 minutes post-drinking (after first vape bout), and 215 minutes post-drinking (after second vape bout). | Biphasic Alcohol Effects Scale Questionnaire (BAES) is a 14-item questionnaire consisting of adjectives that describe the stimulant- and sedative-like effects of alcohol. The items are presented in alphabetical order, and are rated on an 11-point rating scale from 0=Not at All to 10=Extremely. The score for each of the questions was summed to give an overall indication of the individual's subjective intoxication. A higher score would indicate greater feelings of impairment. |
| Subjective High Assessment Scale Questionnaire (SHAS) | Administered at baseline, 55 minutes post-drinking (after first vape bout), and 215 minutes post-drinking (after second vape bout). | Subjective High Assessment Scale Questionnaire (SHAS) is a 14-item questionnaire used to assess how intoxicated a person feels after consuming alcohol, typically administered in laboratory settings. It focuses on capturing subjective sensations associated with intoxication, such as feeling clumsy, dizzy, or high. Participants rate their experience on a visual analog scale (a line with markings) to indicate the extent to which they feel each symptom at a given time. The scale ranges from Normal (0) to Extremely (100). The score for each of the questions is summed to give an overall indication of the individual's subjective intoxication. A higher score would indicate greater feelings of impairment. |
| General Labeled Magnitude Scale Questionnaire (gLMS) | Administered at baseline, 55 minutes post-drinking (after first vape bout), and 215 minutes post-drinking (after second vape bout). | The general labeled magnitude scale (gLMS) is a psychophysical scaling method used to measure the perceived intensity of various sensations. A gLMS typically ranges from 0 (undetectable) to 100 (strongest imaginable sensation/experience of any kind). Crucially, it uses specific labels positioned at specific points on the scale (e.g., barely detectable, weak, moderate, strong, very strong). The gLMS was comprised of 3 questions asking participants to indicate the overall flavor sensation, harshness, and throat hit of the e-cigarette. The score for each of the questions was summed. A higher score would indicate greater sensations from e-cigarette use. |
| Labeled Hedonic Scale Questionnaire (LHS) | Administered at baseline, 55 minutes post-drinking (after first vape bout), and 215 minutes post-drinking (after second vape bout). | A survey tool used to measure how much someone likes or dislikes something using descriptive labels for different levels of liking and disliking. Instead of just numbers, the scale uses words or phrases that describe the intensity of liking or disliking (e.g., most disliked sensation imaginable=0, neutral = 50, and most liked sensation imaginable=100) and aim to provide ratio-level data, meaning that the differences between scale points are meaningful and proportional. the LHS was comprised of 4 questions asking participants to indicate the e-cigarette's overall flavor sensation, harshness, throat hit, and warmth of the vapor. The score for each of the questions was summed. A higher score would indicate a more liked overall vaping experience; a lower score would indicate a more disliked overall vaping experience |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Within Group Four Condition Comparison Participants completed four \
5-hour, Latin-square ordered sessions separated by ≥48 hours. Session order was not recorded as it was not relevant to the study outcomes. Session interventions were as follows:
* Placebo drink: Placebo vape (Beverage without ethanol and E-cigarette liquid without ethanol)
* Placebo drink: Active vape (Beverage without ethanol and E-cigarette liquid with 20% ethanol)
* Active drink: Placebo vape (Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid without ethanol)
* Active drink: Active vape (Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid with 20% ethanol) | 7 |
| Total | 7 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Could not adhere to study schedule | 1 |
| Overall Study | Lost to Follow-up | 4 |
Baseline characteristics
| Characteristic | Within Group Four Condition Comparison |
|---|---|
| Age, Continuous | 24.6 years STANDARD_DEVIATION 3.5 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 7 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 3 Participants |
| Region of Enrollment United States | 7 participants |
| Sex: Female, Male Female | 2 Participants |
| Sex: Female, Male Male | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 7 |
| other Total, other adverse events | 2 / 7 |
| serious Total, serious adverse events | 0 / 7 |
Outcome results
Primary
Blood Alcohol Concentration
Blood alcohol concentration (BAC) level was determined 6 times over 6 hours to assess for changes in BAC from use of an e-cigarette containing ethanol compared to the use of an e-cigarette without ethanol.
Time frame: Blood collected before (baseline) and after (0, 40, 55, 200, 215) drinking. The e-cigarette was used at 50 and 210 minutes post-drinking.
Population: Blood Alcohol Concentration (% alcohol)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | Blood Alcohol Concentration | Baseline Collection | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Blood Alcohol Concentration | 0 Minute Collection Post-Drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Blood Alcohol Concentration | 40 Minute Collection Post-Drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Blood Alcohol Concentration | 55 Minute Collection Post-Drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Blood Alcohol Concentration | 200 Minute Collection Post-Drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Blood Alcohol Concentration | 210 Minute Collection Post-Drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Blood Alcohol Concentration | 210 Minute Collection Post-Drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Blood Alcohol Concentration | 55 Minute Collection Post-Drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Blood Alcohol Concentration | Baseline Collection | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Blood Alcohol Concentration | 40 Minute Collection Post-Drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Blood Alcohol Concentration | 0 Minute Collection Post-Drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Blood Alcohol Concentration | 200 Minute Collection Post-Drinking | 0 percent alcohol | Standard Deviation 0 |
| Active Drink: Placebo Vape | Blood Alcohol Concentration | 0 Minute Collection Post-Drinking | .070 percent alcohol | Standard Deviation 0.037 |
| Active Drink: Placebo Vape | Blood Alcohol Concentration | 40 Minute Collection Post-Drinking | .080 percent alcohol | Standard Deviation 0.022 |
| Active Drink: Placebo Vape | Blood Alcohol Concentration | 55 Minute Collection Post-Drinking | .072 percent alcohol | Standard Deviation 0.016 |
| Active Drink: Placebo Vape | Blood Alcohol Concentration | 210 Minute Collection Post-Drinking | .032 percent alcohol | Standard Deviation 0.013 |
| Active Drink: Placebo Vape | Blood Alcohol Concentration | 200 Minute Collection Post-Drinking | .037 percent alcohol | Standard Deviation 0.013 |
| Active Drink: Placebo Vape | Blood Alcohol Concentration | Baseline Collection | 0 percent alcohol | Standard Deviation 0 |
| Active Drink: Active Vape | Blood Alcohol Concentration | 200 Minute Collection Post-Drinking | .039 percent alcohol | Standard Deviation 0.009 |
| Active Drink: Active Vape | Blood Alcohol Concentration | 210 Minute Collection Post-Drinking | .034 percent alcohol | Standard Deviation 0.011 |
| Active Drink: Active Vape | Blood Alcohol Concentration | 0 Minute Collection Post-Drinking | .061 percent alcohol | Standard Deviation 0.045 |
| Active Drink: Active Vape | Blood Alcohol Concentration | 55 Minute Collection Post-Drinking | .075 percent alcohol | Standard Deviation 0.008 |
| Active Drink: Active Vape | Blood Alcohol Concentration | Baseline Collection | 0 percent alcohol | Standard Deviation 0 |
| Active Drink: Active Vape | Blood Alcohol Concentration | 40 Minute Collection Post-Drinking | .088 percent alcohol | Standard Deviation 0.045 |
Primary
Breath Alcohol Concentration
Breath Alcohol Concentration (BrAC) was assessed 12 times over 6 hours to determine changes in BrAC from the use of an e-cigarette containing ethanol compared to the use of an e-cigarette without ethanol.
Time frame: Breath was analyzed before (baseline) and after (10, 20, 40, 55, 90, 120, 165, 200, 215, 240, 270 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking.
Population: Blood Alcohol Concentration (% alcohol)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | Breath Alcohol Concentration | 215 minute collection post-drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Breath Alcohol Concentration | 270 minute collection post-drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Breath Alcohol Concentration | 165 minute collection post-drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Breath Alcohol Concentration | Baseline | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Breath Alcohol Concentration | 200 minute collection post-drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Breath Alcohol Concentration | 20 minute collection post-drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Breath Alcohol Concentration | 40 minute collection post-drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Breath Alcohol Concentration | 10 minute collection post-drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Breath Alcohol Concentration | 240 minute collection post-drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Breath Alcohol Concentration | 55 minute collection post-drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Breath Alcohol Concentration | 90 minute collection post-drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Breath Alcohol Concentration | 120 minute collection post-drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Breath Alcohol Concentration | 10 minute collection post-drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Breath Alcohol Concentration | 120 minute collection post-drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Breath Alcohol Concentration | 40 minute collection post-drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Breath Alcohol Concentration | 200 minute collection post-drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Breath Alcohol Concentration | 215 minute collection post-drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Breath Alcohol Concentration | 165 minute collection post-drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Breath Alcohol Concentration | Baseline | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Breath Alcohol Concentration | 90 minute collection post-drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Breath Alcohol Concentration | 55 minute collection post-drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Breath Alcohol Concentration | 20 minute collection post-drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Breath Alcohol Concentration | 270 minute collection post-drinking | 0 percent alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Breath Alcohol Concentration | 240 minute collection post-drinking | 0 percent alcohol | Standard Deviation 0 |
| Active Drink: Placebo Vape | Breath Alcohol Concentration | 165 minute collection post-drinking | .033 percent alcohol | Standard Deviation 0.009 |
| Active Drink: Placebo Vape | Breath Alcohol Concentration | Baseline | 0 percent alcohol | Standard Deviation 0 |
| Active Drink: Placebo Vape | Breath Alcohol Concentration | 10 minute collection post-drinking | .069 percent alcohol | Standard Deviation 0.024 |
| Active Drink: Placebo Vape | Breath Alcohol Concentration | 20 minute collection post-drinking | .071 percent alcohol | Standard Deviation 0.024 |
| Active Drink: Placebo Vape | Breath Alcohol Concentration | 40 minute collection post-drinking | .067 percent alcohol | Standard Deviation 0.014 |
| Active Drink: Placebo Vape | Breath Alcohol Concentration | 55 minute collection post-drinking | .054 percent alcohol | Standard Deviation 0.012 |
| Active Drink: Placebo Vape | Breath Alcohol Concentration | 90 minute collection post-drinking | .049 percent alcohol | Standard Deviation 0.011 |
| Active Drink: Placebo Vape | Breath Alcohol Concentration | 120 minute collection post-drinking | .042 percent alcohol | Standard Deviation 0.01 |
| Active Drink: Placebo Vape | Breath Alcohol Concentration | 200 minute collection post-drinking | .026 percent alcohol | Standard Deviation 0.009 |
| Active Drink: Placebo Vape | Breath Alcohol Concentration | 215 minute collection post-drinking | .018 percent alcohol | Standard Deviation 0.006 |
| Active Drink: Placebo Vape | Breath Alcohol Concentration | 240 minute collection post-drinking | .016 percent alcohol | Standard Deviation 0.01 |
| Active Drink: Placebo Vape | Breath Alcohol Concentration | 270 minute collection post-drinking | .009 percent alcohol | Standard Deviation 0.009 |
| Active Drink: Active Vape | Breath Alcohol Concentration | 90 minute collection post-drinking | .053 percent alcohol | Standard Deviation 0.008 |
| Active Drink: Active Vape | Breath Alcohol Concentration | 55 minute collection post-drinking | .061 percent alcohol | Standard Deviation 0.005 |
| Active Drink: Active Vape | Breath Alcohol Concentration | Baseline | 0 percent alcohol | Standard Deviation 0 |
| Active Drink: Active Vape | Breath Alcohol Concentration | 215 minute collection post-drinking | .024 percent alcohol | Standard Deviation 0.005 |
| Active Drink: Active Vape | Breath Alcohol Concentration | 40 minute collection post-drinking | .073 percent alcohol | Standard Deviation 0.012 |
| Active Drink: Active Vape | Breath Alcohol Concentration | 20 minute collection post-drinking | .079 percent alcohol | Standard Deviation 0.025 |
| Active Drink: Active Vape | Breath Alcohol Concentration | 270 minute collection post-drinking | .011 percent alcohol | Standard Deviation 0.009 |
| Active Drink: Active Vape | Breath Alcohol Concentration | 240 minute collection post-drinking | .016 percent alcohol | Standard Deviation 11 |
| Active Drink: Active Vape | Breath Alcohol Concentration | 165 minute collection post-drinking | .035 percent alcohol | Standard Deviation 0.007 |
| Active Drink: Active Vape | Breath Alcohol Concentration | 120 minute collection post-drinking | .045 percent alcohol | Standard Deviation 0.009 |
| Active Drink: Active Vape | Breath Alcohol Concentration | 10 minute collection post-drinking | .080 percent alcohol | Standard Deviation 0.0245 |
| Active Drink: Active Vape | Breath Alcohol Concentration | 200 minute collection post-drinking | .027 percent alcohol | Standard Deviation 0.008 |
Primary
Ethanol Biomarker (5-Hydroxytryptophol) in Blood
5-Hydroxytryptophol was analyzed in blood 6 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol.
Time frame: Blood was collected before (baseline) and after (0, 40, 55, 200, 215 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking.
Population: Ethanol Biomarker (5-Hydroxytryptophol) ng/mL
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
Primary
Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid
5-Hydroxyindoleacetic acid was analyzed in oral fluid 9 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol.
Time frame: Oral fluid was collected before (baseline) and after (0, 5, 20, 40, 55, 200, 215, 240 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking.
Population: Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Oral Fluid ng/mL
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 5 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 5 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 5 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 5 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
Primary
Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood
5-Hydroxyindoleacetic acid was analyzed in blood 6 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol.
Time frame: Blood was collected before (baseline) and after (0, 40, 55, 200, 215 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking.
Population: Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) ng/mL
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | Baseline Collection | 80 ng/mL | Standard Deviation 81 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | 0 minute collection post-drinking | 91 ng/mL | Standard Deviation 97 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | 40 minute collection post-drinking | 97 ng/mL | Standard Deviation 96 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | 55 minute collection post-drinking | 103 ng/mL | Standard Deviation 103 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | 200 minute collection post-drinking | 123 ng/mL | Standard Deviation 98 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | 215 minute collection post-drinking | 82 ng/mL | Standard Deviation 81 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | 215 minute collection post-drinking | 106 ng/mL | Standard Deviation 79 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | 55 minute collection post-drinking | 75 ng/mL | Standard Deviation 99 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | Baseline Collection | 90 ng/mL | Standard Deviation 91 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | 40 minute collection post-drinking | 93 ng/mL | Standard Deviation 93 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | 0 minute collection post-drinking | 34 ng/mL | Standard Deviation 59 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | 200 minute collection post-drinking | 132 ng/mL | Standard Deviation 103 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | 0 minute collection post-drinking | 44 ng/mL | Standard Deviation 29 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | 40 minute collection post-drinking | 30 ng/mL | Standard Deviation 51 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | 55 minute collection post-drinking | 61 ng/mL | Standard Deviation 80 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | 215 minute collection post-drinking | 73 ng/mL | Standard Deviation 97 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | 200 minute collection post-drinking | 71 ng/mL | Standard Deviation 94 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | Baseline Collection | 44 ng/mL | Standard Deviation 75 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | 200 minute collection post-drinking | 90 ng/mL | Standard Deviation 86 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | 215 minute collection post-drinking | 83 ng/mL | Standard Deviation 114 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | 0 minute collection post-drinking | 76 ng/mL | Standard Deviation 36 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | Baseline Collection | 121 ng/mL | Standard Deviation 149 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | 40 minute collection post-drinking | 63 ng/mL | Standard Deviation 81 |
Primary
Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood
5-Hydroxytryptophol glucuronide was analyzed in blood 6 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol.
Time frame: Blood collected before (baseline) and after (0, 40, 55, 200, 215 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking.
Population: Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) in Blood ng/mL
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | Baseline collection | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | Baseline collection | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | Baseline collection | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | Baseline collection | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
Primary
Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid
5-Hydroxyindoleacetic acid was analyzed in oral fluid 9 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol.
Time frame: Oral fluid was collected before (baseline) and after (0, 5, 20, 40, 55, 200, 215, 240 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking
Population: Ethanol Biomarkers (5-Hydroxytryptophol) in Oral Fluid ng/mL
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 5 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | Baseline | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | Baseline | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 5 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | Baseline | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 5 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 5 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | Baseline | 0 ng/mL | Standard Deviation 0 |
Primary
Ethanol Biomarkers (5-Hydroxytryptophol) in Blood
Ethyl glucuronide was analyzed in blood 6 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol.
Time frame: Blood collected before (baseline) and after (0, 40, 55, 200, 215 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking
Population: Ethanol Biomarkers (Ethyl Glucuronide ) in Blood ng/mL
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | Baseline | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | Baseline | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | 40 minute collection post-drinking | 145 ng/mL | Standard Deviation 53 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | 55 minute collection post-drinking | 175 ng/mL | Standard Deviation 52 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | 215 minute collection post-drinking | 325 ng/mL | Standard Deviation 94 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | 200 minute collection post-drinking | 331 ng/mL | Standard Deviation 88 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | Baseline | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | 200 minute collection post-drinking | 406 ng/mL | Standard Deviation 104 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | 215 minute collection post-drinking | 337 ng/mL | Standard Deviation 116 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | 55 minute collection post-drinking | 187 ng/mL | Standard Deviation 41 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | Baseline | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | 40 minute collection post-drinking | 128 ng/mL | Standard Deviation 29 |
Primary
Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood
Ethyl glucuronide was analyzed in blood 6 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol.
Time frame: Blood collected before (baseline) and after (0, 40, 55, 200, 215 min) drinking. The e-cigarette was used by the participant at 50 and 210 minutes post-drinking.
Population: Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) ng/mL
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 5 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 5 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 40 minute collection post-drinking | 145 ng/mL | Standard Deviation 53 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 5 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 55 minute collection post-drinking | 175 ng/mL | Standard Deviation 52 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 200 minute collection post-drinking | 331 ng/mL | Standard Deviation 88 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 215 minute collection post-drinking | 325 ng/mL | Standard Deviation 94 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 200 minute collection post-drinking | 406 ng/mL | Standard Deviation 104 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 5 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 215 minute collection post-drinking | 337 ng/mL | Standard Deviation 116 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 55 minute collection post-drinking | 187 ng/mL | Standard Deviation 41 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | 40 minute collection post-drinking | 128 ng/mL | Standard Deviation 29 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
Primary
Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid
Ethyl glucuronide was analyzed in oral fluid 9 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol.
Time frame: Oral fluid was collected before (baseline) and after (0, 5, 20, 40, 55, 200, 215, 240 min) drinking. The e-cigarette was used by the participant at 50 and 210 minutes post-drinking
Population: Ethanol Biomarkers (Ethyl Glucuronide) in Oral Fluid ng/mL
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 5 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 5 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 5 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 5 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
Primary
Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol
Ethyl sulfate was analyzed in blood 6 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol.
Time frame: Blood was collected before (baseline) and after (0, 40, 55, 200, 215 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking.
Population: Ethanol Biomarkers (Ethyl Sulfate) ng/mL
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | 0 minute collection post-drinking | 16 ng/mL | Standard Deviation 28 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | 40 minute collection post-drinking | 167 ng/mL | Standard Deviation 80 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | 55 minute collection post-drinking | 207 ng/mL | Standard Deviation 67 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | 215 minute collection post-drinking | 218 ng/mL | Standard Deviation 67 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | 200 minute collection post-drinking | 228 ng/mL | Standard Deviation 68 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | 200 minute collection post-drinking | 239 ng/mL | Standard Deviation 55 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | 215 minute collection post-drinking | 224 ng/mL | Standard Deviation 50 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | 0 minute collection post-drinking | 10 ng/mL | Standard Deviation 26 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | 55 minute collection post-drinking | 211 ng/mL | Standard Deviation 46 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | 40 minute collection post-drinking | 184 ng/mL | Standard Deviation 52 |
Primary
Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid
Ethyl sulfate was analyzed in oral fluid 9 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol.
Time frame: Oral fluid was collected before (baseline) and after (0, 5, 20, 40, 55, 200, 215, 240 min) drinking. The e-cigarette was used by the participant at 50 and 210 minutes post-drinking
Population: Ethanol Biomarkers (Ethyl Sulfate) in Oral Fluid ng/mL
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 5 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 5 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 40 minute collection post-drinking | 8 ng/mL | Standard Deviation 21 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 5 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 55 minute collection post-drinking | 26 ng/mL | Standard Deviation 49 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 200 minute collection post-drinking | 25 ng/mL | Standard Deviation 47 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 215 minute collection post-drinking | 29 ng/mL | Standard Deviation 37 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 240 minute collection post-drinking | 33 ng/mL | Standard Deviation 61 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 200 minute collection post-drinking | 53 ng/mL | Standard Deviation 103 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 5 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 240 minute collection post-drinking | 44 ng/mL | Standard Deviation 58 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 215 minute collection post-drinking | 19 ng/mL | Standard Deviation 33 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 55 minute collection post-drinking | 8 ng/mL | Standard Deviation 21 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
Primary
Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood
Phosphatidylethanol 16:0-18:1 was analyzed in oral fluid 9 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol.
Time frame: Oral fluid was collected before (baseline) and after (0, 5, 20, 40, 55, 200, 215, 240 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking.
Population: Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Oral Fluid ng/mL
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 5 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 5 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 5 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 5 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
Primary
Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood
Phosphatidylethanol 16:0-18:1 was analyzed in blood 6 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol.
Time frame: Blood was collected before (baseline) and after (0, 40, 55, 200, 215 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking.
Population: Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood ng/mL
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | Baseline Collection | 402 ng/mL | Standard Deviation 438 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | 0 minute collection post-drinking | 338 ng/mL | Standard Deviation 443 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | 40 minute collection post-drinking | 345 ng/mL | Standard Deviation 460 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | 55 minute collection post-drinking | 330 ng/mL | Standard Deviation 401 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | 200 minute collection post-drinking | 352 ng/mL | Standard Deviation 489 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | 215 minute collection post-drinking | 639 ng/mL | Standard Deviation 739 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | 215 minute collection post-drinking | 411 ng/mL | Standard Deviation 397 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | 55 minute collection post-drinking | 292 ng/mL | Standard Deviation 339 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | Baseline Collection | 416 ng/mL | Standard Deviation 432 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | 40 minute collection post-drinking | 322 ng/mL | Standard Deviation 442 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | 0 minute collection post-drinking | 304 ng/mL | Standard Deviation 433 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | 200 minute collection post-drinking | 302 ng/mL | Standard Deviation 353 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | 0 minute collection post-drinking | 487 ng/mL | Standard Deviation 570 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | 40 minute collection post-drinking | 562 ng/mL | Standard Deviation 688 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | 55 minute collection post-drinking | 589 ng/mL | Standard Deviation 699 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | 215 minute collection post-drinking | 718 ng/mL | Standard Deviation 744 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | 200 minute collection post-drinking | 547 ng/mL | Standard Deviation 722 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | Baseline Collection | 647 ng/mL | Standard Deviation 790 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | 200 minute collection post-drinking | 319 ng/mL | Standard Deviation 297 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | 215 minute collection post-drinking | 450 ng/mL | Standard Deviation 239 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | 0 minute collection post-drinking | 318 ng/mL | Standard Deviation 269 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | 55 minute collection post-drinking | 374 ng/mL | Standard Deviation 284 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | Baseline Collection | 409 ng/mL | Standard Deviation 323 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | 40 minute collection post-drinking | 306 ng/mL | Standard Deviation 270 |
Primary
Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood
Phosphatidylethanol 16:0-18:2 was analyzed in blood 6 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol.
Time frame: Blood was collected before (baseline) and after (0, 40, 55, 200, 215 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking.
Population: Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood ng/mL
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | Baseline Collection | 894 ng/mL | Standard Deviation 956 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | 0 minute collection post-drinking | 549 ng/mL | Standard Deviation 757 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | 40 minute collection post-drinking | 563 ng/mL | Standard Deviation 806 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | 55 minute collection post-drinking | 574 ng/mL | Standard Deviation 758 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | 200 minute collection post-drinking | 636 ng/mL | Standard Deviation 1000 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | 215 minute collection post-drinking | 1630 ng/mL | Standard Deviation 2090 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | 215 minute collection post-drinking | 889 ng/mL | Standard Deviation 873 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | 55 minute collection post-drinking | 466 ng/mL | Standard Deviation 580 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | Baseline Collection | 1013 ng/mL | Standard Deviation 1403 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | 40 minute collection post-drinking | 572 ng/mL | Standard Deviation 768 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | 0 minute collection post-drinking | 549 ng/mL | Standard Deviation 894 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | 200 minute collection post-drinking | 494 ng/mL | Standard Deviation 685 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | 0 minute collection post-drinking | 771 ng/mL | Standard Deviation 939 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | 40 minute collection post-drinking | 927 ng/mL | Standard Deviation 1214 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | 55 minute collection post-drinking | 862 ng/mL | Standard Deviation 1061 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | 215 minute collection post-drinking | 1544 ng/mL | Standard Deviation 1417 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | 200 minute collection post-drinking | 1028 ng/mL | Standard Deviation 1479 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | Baseline Collection | 1256 ng/mL | Standard Deviation 1756 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | 200 minute collection post-drinking | 602 ng/mL | Standard Deviation 500 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | 215 minute collection post-drinking | 1081 ng/mL | Standard Deviation 480 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | 0 minute collection post-drinking | 616 ng/mL | Standard Deviation 577 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | 55 minute collection post-drinking | 832 ng/mL | Standard Deviation 587 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | Baseline Collection | 938 ng/mL | Standard Deviation 784 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | 40 minute collection post-drinking | 617 ng/mL | Standard Deviation 589 |
Primary
Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid
Phosphatidylethanol 16:0-18:2 was analyzed in oral fluid 9 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol.
Time frame: Oral fluid was collected before (baseline) and after (0, 5, 20, 40, 55, 200, 215, 240 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking.
Population: Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid ng/mL
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Placebo Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Placebo Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 20 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 40 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 0 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | Baseline Collection | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 55 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 240 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 215 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
| Active Drink: Active Vape | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | 200 minute collection post-drinking | 0 ng/mL | Standard Deviation 0 |
Primary
Oral Fluid Alcohol Concentration (OFAC)
Oral fluid alcohol concentration (OFAC) was assessed 9 times over 6 hours to determine changes in OFAC from the use of an e-cigarette containing ethanol compared to use of an e-cigarette without ethanol.
Time frame: Oral fluid was collected before (baseline) and after (0, 5, 20, 40, 55, 200, 215, 240 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking.
Population: Blood Alcohol Concentration (% alcohol)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | Oral Fluid Alcohol Concentration (OFAC) | 200 minute collection post-drinking | 0 Percent Alcohol | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Oral Fluid Alcohol Concentration (OFAC) | 55 minute collection post-drinking | 0 Percent Alcohol | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Oral Fluid Alcohol Concentration (OFAC) | 240 minute collection post-drinking | 0 Percent Alcohol | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Oral Fluid Alcohol Concentration (OFAC) | 20 minute collection post-drinking | 0 Percent Alcohol | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Oral Fluid Alcohol Concentration (OFAC) | 5 minute collection post-drinking | 0 Percent Alcohol | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Oral Fluid Alcohol Concentration (OFAC) | 0 minute collection post-drinking | 0 Percent Alcohol | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Oral Fluid Alcohol Concentration (OFAC) | 215 minute collection post-drinking | 0 Percent Alcohol | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Oral Fluid Alcohol Concentration (OFAC) | 40 minute collection post-drinking | 0 Percent Alcohol | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Oral Fluid Alcohol Concentration (OFAC) | Baseline Collection | 0 Percent Alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Oral Fluid Alcohol Concentration (OFAC) | 40 minute collection post-drinking | 0 Percent Alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Oral Fluid Alcohol Concentration (OFAC) | 200 minute collection post-drinking | 0 Percent Alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Oral Fluid Alcohol Concentration (OFAC) | 55 minute collection post-drinking | 0 Percent Alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Oral Fluid Alcohol Concentration (OFAC) | 0 minute collection post-drinking | 0 Percent Alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Oral Fluid Alcohol Concentration (OFAC) | Baseline Collection | 0 Percent Alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Oral Fluid Alcohol Concentration (OFAC) | 5 minute collection post-drinking | 0 Percent Alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Oral Fluid Alcohol Concentration (OFAC) | 240 minute collection post-drinking | 0 Percent Alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Oral Fluid Alcohol Concentration (OFAC) | 215 minute collection post-drinking | 0 Percent Alcohol | Standard Deviation 0 |
| Placebo Drink: Active Vape | Oral Fluid Alcohol Concentration (OFAC) | 20 minute collection post-drinking | 0 Percent Alcohol | Standard Deviation 0 |
| Active Drink: Placebo Vape | Oral Fluid Alcohol Concentration (OFAC) | 40 minute collection post-drinking | .092 Percent Alcohol | Standard Deviation 0.031 |
| Active Drink: Placebo Vape | Oral Fluid Alcohol Concentration (OFAC) | Baseline Collection | 0 Percent Alcohol | Standard Deviation 0 |
| Active Drink: Placebo Vape | Oral Fluid Alcohol Concentration (OFAC) | 0 minute collection post-drinking | .146 Percent Alcohol | Standard Deviation 0.075 |
| Active Drink: Placebo Vape | Oral Fluid Alcohol Concentration (OFAC) | 5 minute collection post-drinking | .118 Percent Alcohol | Standard Deviation 0.055 |
| Active Drink: Placebo Vape | Oral Fluid Alcohol Concentration (OFAC) | 20 minute collection post-drinking | .102 Percent Alcohol | Standard Deviation 0.043 |
| Active Drink: Placebo Vape | Oral Fluid Alcohol Concentration (OFAC) | 55 minute collection post-drinking | .081 Percent Alcohol | Standard Deviation 0.025 |
| Active Drink: Placebo Vape | Oral Fluid Alcohol Concentration (OFAC) | 200 minute collection post-drinking | .036 Percent Alcohol | Standard Deviation 0.014 |
| Active Drink: Placebo Vape | Oral Fluid Alcohol Concentration (OFAC) | 215 minute collection post-drinking | .032 Percent Alcohol | Standard Deviation 0.02 |
| Active Drink: Placebo Vape | Oral Fluid Alcohol Concentration (OFAC) | 240 minute collection post-drinking | .023 Percent Alcohol | Standard Deviation 0.019 |
| Active Drink: Active Vape | Oral Fluid Alcohol Concentration (OFAC) | 200 minute collection post-drinking | .040 Percent Alcohol | Standard Deviation 0.013 |
| Active Drink: Active Vape | Oral Fluid Alcohol Concentration (OFAC) | 20 minute collection post-drinking | .109 Percent Alcohol | Standard Deviation 0.021 |
| Active Drink: Active Vape | Oral Fluid Alcohol Concentration (OFAC) | 5 minute collection post-drinking | .106 Percent Alcohol | Standard Deviation 0.052 |
| Active Drink: Active Vape | Oral Fluid Alcohol Concentration (OFAC) | 240 minute collection post-drinking | .023 Percent Alcohol | Standard Deviation 0.018 |
| Active Drink: Active Vape | Oral Fluid Alcohol Concentration (OFAC) | 215 minute collection post-drinking | .033 Percent Alcohol | Standard Deviation 0.019 |
| Active Drink: Active Vape | Oral Fluid Alcohol Concentration (OFAC) | 0 minute collection post-drinking | .124 Percent Alcohol | Standard Deviation 0.025 |
| Active Drink: Active Vape | Oral Fluid Alcohol Concentration (OFAC) | 55 minute collection post-drinking | .091 Percent Alcohol | Standard Deviation 0.017 |
| Active Drink: Active Vape | Oral Fluid Alcohol Concentration (OFAC) | 40 minute collection post-drinking | .104 Percent Alcohol | Standard Deviation 0.018 |
| Active Drink: Active Vape | Oral Fluid Alcohol Concentration (OFAC) | Baseline Collection | 0 Percent Alcohol | Standard Deviation 0 |
Secondary
Horizontal Gaze Nystagmus
Standard Field Sobriety Tests (SFSTs) were administered 4 times over a course of 6 hours to assess changes in objective impairment. The SFST includes the Horizontal Gaze Nystagmus (a jerking or stuttering type of movement observed in a person's eyes that occurs as a result of consuming alcohol or other nervous system depressants) test. For each test, a law enforcement officer records the number of clues observed. HGN has a maximum of 6 clues, 3 per eye: 1. lack of smooth pursuit 2. distinct and sustained nystagmus at maximum deviation 3. onset of nystagmus prior to 45 degrees.
Time frame: Conducted before drinking (baseline), at 20 minutes post-drinking (before first vaping bout), at 55 minutes post-drinking (after the first vaping), and at 215 minutes post-drinking (after second vaping bout).
Population: Horizontal Gaze Nystagmus # of clues observed
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | Horizontal Gaze Nystagmus | Baseline | 0 Number of Clues Observed | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Horizontal Gaze Nystagmus | Before the 1st Vaping Bout | .4 Number of Clues Observed | Standard Deviation 0.8 |
| Placebo Drink: Placebo Vape | Horizontal Gaze Nystagmus | After the 1st Vaping Bout | .4 Number of Clues Observed | Standard Deviation 0.8 |
| Placebo Drink: Placebo Vape | Horizontal Gaze Nystagmus | After the 2nd Vaping Bout | .3 Number of Clues Observed | Standard Deviation 0.8 |
| Placebo Drink: Active Vape | Horizontal Gaze Nystagmus | Before the 1st Vaping Bout | .9 Number of Clues Observed | Standard Deviation 0.9 |
| Placebo Drink: Active Vape | Horizontal Gaze Nystagmus | After the 2nd Vaping Bout | 1.1 Number of Clues Observed | Standard Deviation 1.5 |
| Placebo Drink: Active Vape | Horizontal Gaze Nystagmus | Baseline | .9 Number of Clues Observed | Standard Deviation 0.9 |
| Placebo Drink: Active Vape | Horizontal Gaze Nystagmus | After the 1st Vaping Bout | .9 Number of Clues Observed | Standard Deviation 1.1 |
| Active Drink: Placebo Vape | Horizontal Gaze Nystagmus | Baseline | .7 Number of Clues Observed | Standard Deviation 1 |
| Active Drink: Placebo Vape | Horizontal Gaze Nystagmus | After the 2nd Vaping Bout | .7 Number of Clues Observed | Standard Deviation 1 |
| Active Drink: Placebo Vape | Horizontal Gaze Nystagmus | After the 1st Vaping Bout | 3.0 Number of Clues Observed | Standard Deviation 1.8 |
| Active Drink: Placebo Vape | Horizontal Gaze Nystagmus | Before the 1st Vaping Bout | 3.1 Number of Clues Observed | Standard Deviation 2.1 |
| Active Drink: Active Vape | Horizontal Gaze Nystagmus | After the 2nd Vaping Bout | 1.9 Number of Clues Observed | Standard Deviation 1.3 |
| Active Drink: Active Vape | Horizontal Gaze Nystagmus | Baseline | .3 Number of Clues Observed | Standard Deviation 0.8 |
| Active Drink: Active Vape | Horizontal Gaze Nystagmus | Before the 1st Vaping Bout | 3.9 Number of Clues Observed | Standard Deviation 1.7 |
| Active Drink: Active Vape | Horizontal Gaze Nystagmus | After the 1st Vaping Bout | 3.4 Number of Clues Observed | Standard Deviation 1.7 |
Secondary
One Leg Stand Test
Standard Field Sobriety Tests (SFSTs) were administered 4 times over a course of 6 hours to assess changes in objective impairment. The SFST includes the one-leg stand test (assess balance and coordination, potentially indicating impairment due to alcohol or drugs). For each test, a law enforcement officer records the number of clues observed. OLS has a maximum of 4 clues: Swaying while balancing, Using arms for balance, Hopping 4. Putting the raised foot down
Time frame: Conducted before drinking (baseline), at 20 minutes post-drinking (before first vaping bout), at 55 minutes post-drinking (after the first vaping), and at 215 minutes post-drinking (after second vaping bout).
Population: One leg stand test, # of clues observed
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | One Leg Stand Test | After the 1st Vaping Bout | .6 Number of Clues observed | Standard Deviation 0.8 |
| Placebo Drink: Placebo Vape | One Leg Stand Test | Before the 1st Vaping Bout | .3 Number of Clues observed | Standard Deviation 0.5 |
| Placebo Drink: Placebo Vape | One Leg Stand Test | Baseline | .6 Number of Clues observed | Standard Deviation 0.8 |
| Placebo Drink: Placebo Vape | One Leg Stand Test | After the 2nd Vaping Bout | .6 Number of Clues observed | Standard Deviation 0.8 |
| Placebo Drink: Active Vape | One Leg Stand Test | Before the 1st Vaping Bout | 0 Number of Clues observed | Standard Deviation 0 |
| Placebo Drink: Active Vape | One Leg Stand Test | After the 2nd Vaping Bout | .3 Number of Clues observed | Standard Deviation 0.5 |
| Placebo Drink: Active Vape | One Leg Stand Test | Baseline | .7 Number of Clues observed | Standard Deviation 1.1 |
| Placebo Drink: Active Vape | One Leg Stand Test | After the 1st Vaping Bout | .3 Number of Clues observed | Standard Deviation 0.5 |
| Active Drink: Placebo Vape | One Leg Stand Test | Baseline | .4 Number of Clues observed | Standard Deviation 0.5 |
| Active Drink: Placebo Vape | One Leg Stand Test | After the 2nd Vaping Bout | .3 Number of Clues observed | Standard Deviation 0.5 |
| Active Drink: Placebo Vape | One Leg Stand Test | After the 1st Vaping Bout | .4 Number of Clues observed | Standard Deviation 0.8 |
| Active Drink: Placebo Vape | One Leg Stand Test | Before the 1st Vaping Bout | .9 Number of Clues observed | Standard Deviation 1.5 |
| Active Drink: Active Vape | One Leg Stand Test | After the 2nd Vaping Bout | .4 Number of Clues observed | Standard Deviation 0.8 |
| Active Drink: Active Vape | One Leg Stand Test | Baseline | .7 Number of Clues observed | Standard Deviation 0.8 |
| Active Drink: Active Vape | One Leg Stand Test | Before the 1st Vaping Bout | 1 Number of Clues observed | Standard Deviation 1.3 |
| Active Drink: Active Vape | One Leg Stand Test | After the 1st Vaping Bout | 1.1 Number of Clues observed | Standard Deviation 1.3 |
Secondary
Walk and Turn Test
Standard Field Sobriety Tests (SFSTs) were administered 4 times over a course of 6 hours to assess changes in objective impairment. The SFST includes the walk and turn test (suspect to perform a physical task while simultaneously following instructions and maintaining balance; involves walking a straight line heel-to-toe, turning, and walking back, with officers looking for specific indicators of impairment). For each test, a law enforcement officer records the number of clues observed. WAT has a maximum of 8 clues: 1. inability to balance during the instruction phase 2. starting before the officer has finished the instructions 3. Stopping while walking to regain balance 4. Not touching heel-to-toe 5. Stepping off the line 6. Using arms to balance 7. Losing balance on the turn or turning incorrectly 8. Taking the wrong number of steps
Time frame: Conducted before drinking (baseline), at 20 minutes post-drinking (before first vaping bout), at 55 minutes post-drinking (after the first vaping), and at 215 minutes post-drinking (after second vaping bout).
Population: Walk and Turn Test, # of clues observed
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | Walk and Turn Test | Baseline | .6 Number of Clues Observed | Standard Deviation 0.8 |
| Placebo Drink: Placebo Vape | Walk and Turn Test | Before the 1st Vaping Bout | .4 Number of Clues Observed | Standard Deviation 0.8 |
| Placebo Drink: Placebo Vape | Walk and Turn Test | After the 1st Vaping Bout | .3 Number of Clues Observed | Standard Deviation 0.5 |
| Placebo Drink: Placebo Vape | Walk and Turn Test | After the 2nd Vaping Bout | .1 Number of Clues Observed | Standard Deviation 0.4 |
| Placebo Drink: Active Vape | Walk and Turn Test | Before the 1st Vaping Bout | .9 Number of Clues Observed | Standard Deviation 0.7 |
| Placebo Drink: Active Vape | Walk and Turn Test | After the 1st Vaping Bout | .4 Number of Clues Observed | Standard Deviation 0.8 |
| Placebo Drink: Active Vape | Walk and Turn Test | After the 2nd Vaping Bout | .7 Number of Clues Observed | Standard Deviation 0.8 |
| Placebo Drink: Active Vape | Walk and Turn Test | Baseline | .9 Number of Clues Observed | Standard Deviation 1.1 |
| Active Drink: Placebo Vape | Walk and Turn Test | After the 1st Vaping Bout | 1.0 Number of Clues Observed | Standard Deviation 1.3 |
| Active Drink: Placebo Vape | Walk and Turn Test | Before the 1st Vaping Bout | 1.1 Number of Clues Observed | Standard Deviation 1.3 |
| Active Drink: Placebo Vape | Walk and Turn Test | After the 2nd Vaping Bout | .6 Number of Clues Observed | Standard Deviation 0.5 |
| Active Drink: Placebo Vape | Walk and Turn Test | Baseline | .9 Number of Clues Observed | Standard Deviation 0.9 |
| Active Drink: Active Vape | Walk and Turn Test | After the 2nd Vaping Bout | .7 Number of Clues Observed | Standard Deviation 0.8 |
| Active Drink: Active Vape | Walk and Turn Test | Before the 1st Vaping Bout | 1.1 Number of Clues Observed | Standard Deviation 1.2 |
| Active Drink: Active Vape | Walk and Turn Test | Baseline | .6 Number of Clues Observed | Standard Deviation 0.5 |
| Active Drink: Active Vape | Walk and Turn Test | After the 1st Vaping Bout | 1.1 Number of Clues Observed | Standard Deviation 1.1 |
Other Pre-specified
Biphasic Alcohol Effects Scale Questionnaire (BAES)
Biphasic Alcohol Effects Scale Questionnaire (BAES) is a 14-item questionnaire consisting of adjectives that describe the stimulant- and sedative-like effects of alcohol. The items are presented in alphabetical order, and are rated on an 11-point rating scale from 0=Not at All to 10=Extremely. The score for each of the questions was summed to give an overall indication of the individual's subjective intoxication. A higher score would indicate greater feelings of impairment.
Time frame: Administered at baseline, 55 minutes post-drinking (after first vape bout), and 215 minutes post-drinking (after second vape bout).
Population: Biphasic Alcohol Effects Scale Questionnaire (BAES) total score
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | Biphasic Alcohol Effects Scale Questionnaire (BAES) | Baseline | 22 (BAES) total score | Standard Deviation 15 |
| Placebo Drink: Placebo Vape | Biphasic Alcohol Effects Scale Questionnaire (BAES) | After e-cig use at 215 minutes | 24 (BAES) total score | Standard Deviation 14 |
| Placebo Drink: Placebo Vape | Biphasic Alcohol Effects Scale Questionnaire (BAES) | After e-cig use at 55 minutes | 22 (BAES) total score | Standard Deviation 11 |
| Placebo Drink: Active Vape | Biphasic Alcohol Effects Scale Questionnaire (BAES) | Baseline | 25 (BAES) total score | Standard Deviation 11 |
| Placebo Drink: Active Vape | Biphasic Alcohol Effects Scale Questionnaire (BAES) | After e-cig use at 215 minutes | 24 (BAES) total score | Standard Deviation 14 |
| Placebo Drink: Active Vape | Biphasic Alcohol Effects Scale Questionnaire (BAES) | After e-cig use at 55 minutes | 25 (BAES) total score | Standard Deviation 11 |
| Active Drink: Placebo Vape | Biphasic Alcohol Effects Scale Questionnaire (BAES) | After e-cig use at 55 minutes | 33 (BAES) total score | Standard Deviation 17 |
| Active Drink: Placebo Vape | Biphasic Alcohol Effects Scale Questionnaire (BAES) | Baseline | 28 (BAES) total score | Standard Deviation 15 |
| Active Drink: Placebo Vape | Biphasic Alcohol Effects Scale Questionnaire (BAES) | After e-cig use at 215 minutes | 28 (BAES) total score | Standard Deviation 12 |
| Active Drink: Active Vape | Biphasic Alcohol Effects Scale Questionnaire (BAES) | Baseline | 25 (BAES) total score | Standard Deviation 14 |
| Active Drink: Active Vape | Biphasic Alcohol Effects Scale Questionnaire (BAES) | After e-cig use at 215 minutes | 32 (BAES) total score | Standard Deviation 12 |
| Active Drink: Active Vape | Biphasic Alcohol Effects Scale Questionnaire (BAES) | After e-cig use at 55 minutes | 36 (BAES) total score | Standard Deviation 14 |
Other Pre-specified
Direct Effects of Vaping Questionnaire (DEPVQ)
Direct Effects of Vaping Questionnaire (DEVQ) is a 10-item Questionnaire that asks participants about their vaping experience (10 questions, each scored from 0 - 100). While subscale scores are often the primary focus, an overall score may be calculated by summing all item scores or averaging them. The score for each of the questions was summed. A higher score indicates the e-cigarette evoked greater subjective effects or feelings.
Time frame: Administered at baseline, 55 minutes post-drinking (after first vape bout), and 215 minutes post-drinking (after second vape bout).
Population: Direct Effects of Vaping Questionnaire (DEPVQ) total score
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | Direct Effects of Vaping Questionnaire (DEPVQ) | Baseline | 0 (DEPVQ) total score | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Direct Effects of Vaping Questionnaire (DEPVQ) | After e-cig use at 215 minutes | 255 (DEPVQ) total score | Standard Deviation 117 |
| Placebo Drink: Placebo Vape | Direct Effects of Vaping Questionnaire (DEPVQ) | After e-cig use at 55 minutes | 320 (DEPVQ) total score | Standard Deviation 132 |
| Placebo Drink: Active Vape | Direct Effects of Vaping Questionnaire (DEPVQ) | Baseline | 0 (DEPVQ) total score | Standard Deviation 0 |
| Placebo Drink: Active Vape | Direct Effects of Vaping Questionnaire (DEPVQ) | After e-cig use at 215 minutes | 205 (DEPVQ) total score | Standard Deviation 108 |
| Placebo Drink: Active Vape | Direct Effects of Vaping Questionnaire (DEPVQ) | After e-cig use at 55 minutes | 259 (DEPVQ) total score | Standard Deviation 151 |
| Active Drink: Placebo Vape | Direct Effects of Vaping Questionnaire (DEPVQ) | After e-cig use at 55 minutes | 289 (DEPVQ) total score | Standard Deviation 183 |
| Active Drink: Placebo Vape | Direct Effects of Vaping Questionnaire (DEPVQ) | Baseline | 0 (DEPVQ) total score | Standard Deviation 0 |
| Active Drink: Placebo Vape | Direct Effects of Vaping Questionnaire (DEPVQ) | After e-cig use at 215 minutes | 259 (DEPVQ) total score | Standard Deviation 112 |
| Active Drink: Active Vape | Direct Effects of Vaping Questionnaire (DEPVQ) | Baseline | 0 (DEPVQ) total score | Standard Deviation 0 |
| Active Drink: Active Vape | Direct Effects of Vaping Questionnaire (DEPVQ) | After e-cig use at 215 minutes | 243 (DEPVQ) total score | Standard Deviation 128 |
| Active Drink: Active Vape | Direct Effects of Vaping Questionnaire (DEPVQ) | After e-cig use at 55 minutes | 309 (DEPVQ) total score | Standard Deviation 136 |
Other Pre-specified
General Labeled Magnitude Scale Questionnaire (gLMS)
The general labeled magnitude scale (gLMS) is a psychophysical scaling method used to measure the perceived intensity of various sensations. A gLMS typically ranges from 0 (undetectable) to 100 (strongest imaginable sensation/experience of any kind). Crucially, it uses specific labels positioned at specific points on the scale (e.g., barely detectable, weak, moderate, strong, very strong). The gLMS was comprised of 3 questions asking participants to indicate the overall flavor sensation, harshness, and throat hit of the e-cigarette. The score for each of the questions was summed. A higher score would indicate greater sensations from e-cigarette use.
Time frame: Administered at baseline, 55 minutes post-drinking (after first vape bout), and 215 minutes post-drinking (after second vape bout).
Population: General Labeled Magnitude Scale Questionnaire (gLMS) total score
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | General Labeled Magnitude Scale Questionnaire (gLMS) | Baseline | 0 (gLMS) total score | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | General Labeled Magnitude Scale Questionnaire (gLMS) | After e-cig use at 215 minutes | 83 (gLMS) total score | Standard Deviation 63 |
| Placebo Drink: Placebo Vape | General Labeled Magnitude Scale Questionnaire (gLMS) | After e-cig use at 55 minutes | 91 (gLMS) total score | Standard Deviation 51 |
| Placebo Drink: Active Vape | General Labeled Magnitude Scale Questionnaire (gLMS) | Baseline | 0 (gLMS) total score | Standard Deviation 0 |
| Placebo Drink: Active Vape | General Labeled Magnitude Scale Questionnaire (gLMS) | After e-cig use at 215 minutes | 105 (gLMS) total score | Standard Deviation 67 |
| Placebo Drink: Active Vape | General Labeled Magnitude Scale Questionnaire (gLMS) | After e-cig use at 55 minutes | 108 (gLMS) total score | Standard Deviation 58 |
| Active Drink: Placebo Vape | General Labeled Magnitude Scale Questionnaire (gLMS) | After e-cig use at 55 minutes | 86 (gLMS) total score | Standard Deviation 66 |
| Active Drink: Placebo Vape | General Labeled Magnitude Scale Questionnaire (gLMS) | Baseline | 0 (gLMS) total score | Standard Deviation 0 |
| Active Drink: Placebo Vape | General Labeled Magnitude Scale Questionnaire (gLMS) | After e-cig use at 215 minutes | 101 (gLMS) total score | Standard Deviation 61 |
| Active Drink: Active Vape | General Labeled Magnitude Scale Questionnaire (gLMS) | Baseline | 0 (gLMS) total score | Standard Deviation 0 |
| Active Drink: Active Vape | General Labeled Magnitude Scale Questionnaire (gLMS) | After e-cig use at 215 minutes | 81 (gLMS) total score | Standard Deviation 69 |
| Active Drink: Active Vape | General Labeled Magnitude Scale Questionnaire (gLMS) | After e-cig use at 55 minutes | 105 (gLMS) total score | Standard Deviation 57 |
Other Pre-specified
Labeled Hedonic Scale Questionnaire (LHS)
A survey tool used to measure how much someone likes or dislikes something using descriptive labels for different levels of liking and disliking. Instead of just numbers, the scale uses words or phrases that describe the intensity of liking or disliking (e.g., most disliked sensation imaginable=0, neutral = 50, and most liked sensation imaginable=100) and aim to provide ratio-level data, meaning that the differences between scale points are meaningful and proportional. the LHS was comprised of 4 questions asking participants to indicate the e-cigarette's overall flavor sensation, harshness, throat hit, and warmth of the vapor. The score for each of the questions was summed. A higher score would indicate a more liked overall vaping experience; a lower score would indicate a more disliked overall vaping experience
Time frame: Administered at baseline, 55 minutes post-drinking (after first vape bout), and 215 minutes post-drinking (after second vape bout).
Population: Labeled Hedonic Scale Questionnaire (LHS) total score
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | Labeled Hedonic Scale Questionnaire (LHS) | Baseline | 0 (LHS) total score | Standard Deviation 0 |
| Placebo Drink: Placebo Vape | Labeled Hedonic Scale Questionnaire (LHS) | After e-cig use at 215 minutes | 180 (LHS) total score | Standard Deviation 44 |
| Placebo Drink: Placebo Vape | Labeled Hedonic Scale Questionnaire (LHS) | After e-cig use at 55 minutes | 161 (LHS) total score | Standard Deviation 37 |
| Placebo Drink: Active Vape | Labeled Hedonic Scale Questionnaire (LHS) | After e-cig use at 215 minutes | 121 (LHS) total score | Standard Deviation 55 |
| Placebo Drink: Active Vape | Labeled Hedonic Scale Questionnaire (LHS) | Baseline | 0 (LHS) total score | Standard Deviation 0 |
| Placebo Drink: Active Vape | Labeled Hedonic Scale Questionnaire (LHS) | After e-cig use at 55 minutes | 125 (LHS) total score | Standard Deviation 42 |
| Active Drink: Placebo Vape | Labeled Hedonic Scale Questionnaire (LHS) | After e-cig use at 55 minutes | 184 (LHS) total score | Standard Deviation 71 |
| Active Drink: Placebo Vape | Labeled Hedonic Scale Questionnaire (LHS) | Baseline | 0 (LHS) total score | Standard Deviation 0 |
| Active Drink: Placebo Vape | Labeled Hedonic Scale Questionnaire (LHS) | After e-cig use at 215 minutes | 152 (LHS) total score | Standard Deviation 81 |
| Active Drink: Active Vape | Labeled Hedonic Scale Questionnaire (LHS) | Baseline | 0 (LHS) total score | Standard Deviation 0 |
| Active Drink: Active Vape | Labeled Hedonic Scale Questionnaire (LHS) | After e-cig use at 215 minutes | 152 (LHS) total score | Standard Deviation 61 |
| Active Drink: Active Vape | Labeled Hedonic Scale Questionnaire (LHS) | After e-cig use at 55 minutes | 165 (LHS) total score | Standard Deviation 66 |
Other Pre-specified
Subjective High Assessment Scale Questionnaire (SHAS)
Subjective High Assessment Scale Questionnaire (SHAS) is a 14-item questionnaire used to assess how intoxicated a person feels after consuming alcohol, typically administered in laboratory settings. It focuses on capturing subjective sensations associated with intoxication, such as feeling clumsy, dizzy, or high. Participants rate their experience on a visual analog scale (a line with markings) to indicate the extent to which they feel each symptom at a given time. The scale ranges from Normal (0) to Extremely (100). The score for each of the questions is summed to give an overall indication of the individual's subjective intoxication. A higher score would indicate greater feelings of impairment.
Time frame: Administered at baseline, 55 minutes post-drinking (after first vape bout), and 215 minutes post-drinking (after second vape bout).
Population: Subjective High Assessment Scale Questionnaire (SHAS) Total score
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Drink: Placebo Vape | Subjective High Assessment Scale Questionnaire (SHAS) | Baseline | 60 SHAS Total score | Standard Deviation 74 |
| Placebo Drink: Placebo Vape | Subjective High Assessment Scale Questionnaire (SHAS) | After e-cig use at 215 minutes | 52 SHAS Total score | Standard Deviation 47 |
| Placebo Drink: Placebo Vape | Subjective High Assessment Scale Questionnaire (SHAS) | After e-cig use at 55 minutes | 91 SHAS Total score | Standard Deviation 64 |
| Placebo Drink: Active Vape | Subjective High Assessment Scale Questionnaire (SHAS) | Baseline | 58 SHAS Total score | Standard Deviation 75 |
| Placebo Drink: Active Vape | Subjective High Assessment Scale Questionnaire (SHAS) | After e-cig use at 215 minutes | 48 SHAS Total score | Standard Deviation 51 |
| Placebo Drink: Active Vape | Subjective High Assessment Scale Questionnaire (SHAS) | After e-cig use at 55 minutes | 78 SHAS Total score | Standard Deviation 71 |
| Active Drink: Placebo Vape | Subjective High Assessment Scale Questionnaire (SHAS) | After e-cig use at 55 minutes | 244 SHAS Total score | Standard Deviation 271 |
| Active Drink: Placebo Vape | Subjective High Assessment Scale Questionnaire (SHAS) | Baseline | 38 SHAS Total score | Standard Deviation 41 |
| Active Drink: Placebo Vape | Subjective High Assessment Scale Questionnaire (SHAS) | After e-cig use at 215 minutes | 105 SHAS Total score | Standard Deviation 132 |
| Active Drink: Active Vape | Subjective High Assessment Scale Questionnaire (SHAS) | Baseline | 29 SHAS Total score | Standard Deviation 30 |
| Active Drink: Active Vape | Subjective High Assessment Scale Questionnaire (SHAS) | After e-cig use at 215 minutes | 172 SHAS Total score | Standard Deviation 229 |
| Active Drink: Active Vape | Subjective High Assessment Scale Questionnaire (SHAS) | After e-cig use at 55 minutes | 286 SHAS Total score | Standard Deviation 241 |